Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer

International Journal of Gynecological Cancer - Tập 27 Số 4 - Trang 738-742 - 2017
Ji Young Hwang1, Da Hee Kim1, Hyo Sook Bae1, Mi‐La Kim1, Yong Wook Jung1, Bo Seong Yun1, Seok Ju Seong1, Eunah Shin2, Mi Kyoung Kim3
1Departments of Obstetrics and Gynecology and
2Pathology CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea.
3MD, Department of Obstetrics & Gynecology, CHA Gangnam Medical Center, CHA University, 566, Nonhyeon-ro, Gangnam-gu, Seoul 135-081, Republic of Korea. E-mail: rlaalrud80{at}hanmail.net.

Tóm tắt

ObjectiveThe aim of this study was to evaluate the oncologic and pregnancy outcomes of combined oral medroxyprogesterone acetate (MPA)/levonorgestrel-intrauterine system (LNG-IUS) treatment in young women with grade 2–differentiated stage IA endometrial adenocarcinoma who wish to preserve fertility.MethodsWe retrospectively reviewed the medical records of patients with grade 2 stage IA endometrial adenocarcinoma who had received fertility-sparing treatment at CHA Gangnam Medical Center between 2011 and 2015. All of the patients were treated with combined oral MPA (500 mg/d)/LNG-IUS, and follow-up dilatation and curettage were performed every 3 months.ResultsA total of 5 patients were included in the study. The mean age was 30.4 ± 5.3 years (range, 25–39 years). After a mean treatment duration of 11.0 ± 6.2 months (range, 6–18 months), complete response (CR) was shown in 3 of the 5 patients, with partial response (PR) in the other 2 patients. One case of recurrence was reported 14 months after achieving CR. This patient was treated again with combined oral MPA/LNG-IUS and achieved CR by 6 months. The average follow-up period was 44.4 ± 26.2 months (range, 12–71 months). There were no cases of progressive disease. No treatment-related complications arose.ConclusionsCombined oral MPA/LNG-IUS treatment is considered to be a reasonably effective fertility-sparing treatment of grade 2 stage IA endometrial cancer. Although our results are encouraging, it is preliminary and should be considered with experienced oncologists in well-defined protocol and with close follow-up.

Từ khóa


Tài liệu tham khảo

Crissman, 1981, Obstet Gynecol, 57, 699

Pellerin, 2005, Am J Obstet Gynecol, 193, 1640, 10.1016/j.ajog.2005.05.003

Kim, 1997, Cancer, 79, 320, 10.1002/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2

Randall, 1997, Obstet Gynecol, 90, 434, 10.1016/S0029-7844(97)00297-4

Imai, 2001, Eur J Gynaecol Oncol, 22, 217

Kaku, 2001, Cancer Lett, 167, 39, 10.1016/S0304-3835(01)00462-1

Wang, 2002, Cancer, 94, 2192, 10.1002/cncr.10435

Jadoul, 2003, Fertil Steril, 80, 1315, 10.1016/S0015-0282(03)01183-X

Ushijima, 2007, J Clin Oncol, 25, 2798, 10.1200/JCO.2006.08.8344

Kesterson, 2012, J Gynecol Oncol, 23, 120, 10.3802/jgo.2012.23.2.120

Wang, 2014, Int J Gynecol Cancer, 24, 718, 10.1097/IGC.0000000000000098

Baker, 2012, Gynecol Oncol, 125, 263, 10.1016/j.ygyno.2011.11.043

Kim, 2013, Am J Obstet Gynecol, 209, 358.e1, 10.1016/j.ajog.2013.06.031

Kim, 2013, Obstet Gynecol Sci, 56, 67, 10.5468/OGS.2013.56.2.67

Sardi, 1998, Eur J Gynaecol Oncol, 19, 565

Zuckerman, 1998, Int J Gynecol Cancer, 8, 172, 10.1046/j.1525-1438.1998.97100.x

Gotlieb, 2003, Obstet Gynecol, 102, 718

Koskas, 2011, Anticancer Res, 31, 3047

Brown, 2012, Obstet Gynecol, 119, 423, 10.1097/AOG.0b013e318234d97c

Park, 2013, Obstet Gynecol, 122, 7, 10.1097/AOG.0b013e3182964ce3

Kurman, 1991, Verh Dtsch Ges Pathol, 75, 376

Nofech-Mozes, 2012, Obstet Gynecol Int, 2012, 414086, 10.1155/2012/414086

Taylor, 1999, Gynecol Oncol, 74, 3, 10.1006/gyno.1999.5422

Thigpen, 1999, J Clin Oncol, 17, 1736, 10.1200/JCO.1999.17.6.1736

Gotlieb, 2013, Gynecol Oncol, 129, 1, 10.1016/j.ygyno.2013.02.031

Thông tin
Thông tin xuất bản

International Journal of Gynecological Cancer

Tập 27 Số 4

738-742

Thông tin tác giả